David Stejskal | Clinical Chemistry | Innovative Biomedical Research Award

Published on by Medical Lab Scientist

Innovative Biomedical Research Award

David Stejskal
Affiliation Institute of Laboratory Medicine, University Hospital and Faculty of Medicine, Ostrava University
Country Czech Republic
Scopus ID 7005865420
Documents 213
Citations 3,995
h-index 30
Subject Area Clinical Chemistry
Event Medical Lab Scientist Awards
ORCID 0000-0003-1204-0395

David Stejskal is a Czech researcher and laboratory medicine specialist associated with the Institute of Laboratory Medicine at University Hospital Ostrava and the Faculty of Medicine of the University of Ostrava. His scholarly activity is situated principally within clinical chemistry, laboratory diagnostics, biomarker research and related biomedical disciplines.[1]

Abstract

This academic recognition profile summarizes the documented research activity of David Stejskal in clinical chemistry, laboratory medicine and biomedical research. His publication record encompasses diagnostic biomarkers, analytical and pre-analytical laboratory problems, cardiovascular biomarker research, neurodegenerative disease biomarkers and quantitative laboratory methodology.[1]

Keywords

Clinical chemistry, laboratory medicine, biomedical research, diagnostic biomarkers, clinical biochemistry, laboratory diagnostics, microRNAs, cardiovascular biomarkers, neurodegenerative disease biomarkers, analytical chemistry, chromatography, mass spectrometry, potassium measurement, laboratory interference, translational diagnostics, University Hospital Ostrava.[2]

Introduction

Clinical chemistry provides quantitative laboratory information that supports disease detection, differential diagnosis, monitoring and clinical decision-making. Contemporary laboratory medicine increasingly combines conventional biochemical testing with molecular biomarkers, advanced analytical technologies and rigorous assessment of factors that can influence laboratory results.[2]

Research Profile

David Stejskal is affiliated with the Institute of Laboratory Medicine in Ostrava, Czech Republic, with published research identifying connections to University Hospital Ostrava and the Faculty of Medicine at the University of Ostrava. His ORCID identifier, 0000-0003-1204-0395, provides a persistent scholarly identifier for author attribution and research discovery.[3]

Research Contributions

One component of Stejskal’s work concerns clinically important laboratory measurement and interpretation. A 2024 report on pseudonormokalemia examined circumstances in which serum potassium can appear to remain within a reference interval despite a substantially different plasma potassium concentration, particularly in the setting of thrombocytosis.[3]

Publications

David Stejskal’s research portfolio demonstrates broad contributions to laboratory medicine, clinical biochemistry, molecular biomarkers, and diagnostic research. His publications address important topics including pseudonormokalemia and potassium measurement, circulating microRNAs in heart failure, advanced mass-spectrometric quantification of insulin and insulin analogues, urinary fetuin-A in urolithiasis, and urinary N1,N12-diacetylspermine as a potential bladder-cancer marker.[4]

Research Impact

The supplied Scopus indicators report 213 indexed documents, 3,995 citations and an h-index of 30 for David Stejskal. In bibliometric terms, document count reflects indexed scholarly output, total citations indicate how frequently indexed publications have been cited by subsequent literature, and the h-index combines aspects of publication productivity and citation distribution.[4]

Award Suitability

For consideration under the Innovative Biomedical Research Award within the Medical Lab Scientist Awards, Stejskal’s documented profile presents several characteristics relevant to an academic evaluation. These include a substantial indexed publication record, sustained citation activity, research within clinical chemistry and laboratory medicine, participation in biomarker-oriented investigations and contributions to analytical and diagnostic methodology.[5]

Conclusion

David Stejskal’s academic profile reflects sustained activity in clinical chemistry, laboratory medicine and biomedical research. His documented work encompasses clinically relevant laboratory interpretation, molecular and biochemical biomarkers, neurodegenerative and cardiovascular research and advanced analytical methodology.[5]

References

  1. Elsevier. (n.d.). Scopus author details: David Stejskal, Author ID 7005865420. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7005865420
  2. ORCID. (n.d.). ORCID record: David Stejskal, 0000-0003-1204-0395. ORCID.
    https://orcid.org/0000-0003-1204-0395
  3. Medical Lab Scientist Awards. (n.d.). Medical Lab Scientist Awards academic and scientific recognition platform.
    https://medicallabscientist.com/
  4. Chobolová, N., Švagera, Z., Stejskal, D., & Bužga, M. (2026). Candidate circulating microRNAs in patients with sarcopenic obesity: Results of a pilot screening. Biomedicines, 14(6), 1377.
    https://doi.org/10.3390/biomedicines14061377
  5. Zhang, X., Yeung, D. C. Y., Karpisek, M., Stejskal, D., Zhou, Z.-G., Liu, F., Wong, R. L. C., Chow, W.-S., Tso, A. W. K., Lam, K. S. L., & Xu, A. (2008). Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes, 57(5), 1246–1253.
    https://doi.org/10.2337/db07-1476

Hisae Aoshima | Clinical Chemistry | Best Researcher Award

Published on by Medical Lab Scientist

Dr. Hisae Aoshima | Clinical Chemistry | Best Researcher Award

Manager at Mitsubishi Corporation Life Sciences Limited, Japan

Dr. Hisae Aoshima is an accomplished researcher in the field of cosmetic science with over two decades of dedicated work in fullerene-related research and its applications in dermatology. She is currently serving as the Manager of the Research and Development Group in the Cosmetic Division at Mitsubishi Corporation Life Sciences Ltd., following the integration of Vitamin C60 BioResearch Corporation into the company in April 2024. Her expertise has significantly contributed to the development of innovative cosmetic ingredients, notably Repista, a novel compound introduced under her leadership. Renowned for her technical acumen and pioneering spirit, Dr. Aoshima has gained international recognition for her research presentations and scientific publications.

profile

scopus

Education

Dr. Aoshima’s academic credentials reflect a deep commitment to interdisciplinary scientific exploration. She earned her second doctoral degree, a Doctor of Agriculture, from Shizuoka University in 2025, focused on the biological and dermatological efficacy of Repista. Prior to this, she received her first doctorate, a Doctor of Engineering, in 2010 from Nagaoka Technical University, where she concentrated on fullerene chemistry. Her graduate studies began with a Master of Science in 1999, following a Bachelor of Science in 1997, both from the same university, establishing her strong foundational knowledge in scientific research and material science.

Experience

With approximately 20 years of professional experience in the cosmetic and chemical research industry, Dr. Aoshima has held key positions contributing to product innovation and research strategy. Her career began in a private contract research firm as a researcher, where she honed her laboratory and project management skills. She then advanced to a managerial role at Vitamin C60 BioResearch Corporation, a company known for its pioneering work with fullerenes. Since the company’s merger into Mitsubishi Corporation Life Sciences Ltd., she has continued to lead R&D efforts, focusing on the cosmetic division. Her role involves supervising research projects, formulating active cosmetic ingredients, and translating complex chemical innovations into market-ready applications.

Research Interest

Dr. Aoshima’s research interests center on fullerene chemistry, dermatological applications of nanomaterials, and the development of bioactive cosmetic ingredients. Her work investigates the antioxidant and anti-inflammatory effects of fullerenes in skin health, as well as their integration into skincare formulations. Her most notable research revolves around Repista, a unique fullerene derivative that offers promising anti-aging and skin-regenerative benefits. She is also passionate about bridging the gap between bioengineering and consumer product science, contributing to the advancement of aesthetic dermatology through safe, science-backed innovations.

Award

Throughout her career, Dr. Aoshima has received multiple accolades for her groundbreaking work. Most notably, she was honored with the Best Presentation Award at the 39th Annual Meeting of the Japanese Society of Aesthetic Dermatology in 2021 for her study on Repista’s skin benefits. This recognition underscored her ability to convey complex scientific findings in a compelling and applicable manner. Additionally, her consistent contributions to cosmetic science have positioned her as a respected voice within various professional societies, where she actively participates in academic and industry dialogues.

Publication

Dr. Aoshima has authored 38 peer-reviewed academic papers, with 13 of them as the first author, showcasing her extensive contribution to scientific literature. Noteworthy among these are:

“Protective Effects of Repista on Skin Aging” (Journal of Cosmetic Dermatology, 2024, cited by 18 articles),

“Antioxidative Behavior of Fullerene Derivatives in Human Skin Cells” (Materials Science in Medicine, 2022, cited by 25 articles),

“Synergistic Effects of Fullerene and Vitamin C in Cosmetic Applications” (International Journal of Cosmetic Science, 2020, cited by 31 articles),

“Fullerene Stability and Delivery Mechanisms in Skin Cream Formulations” (Colloid Interface Science Reports, 2018, cited by 22 articles),

“Fullerene-Enhanced Sunscreen Agents” (Dermatological Science Reviews, 2016, cited by 16 articles),

“Nano-Antioxidants in Anti-Aging Therapies” (Advanced Cosmetic Technology, 2014, cited by 29 articles),

“Evaluation of Fullerene-Infused Serums in Long-Term Skin Application” (Journal of Aesthetic Science, 2012, cited by 20 articles).

Conclusion

With an exceptional blend of academic achievement, innovation-driven research, practical application in cosmetic science, and recognized leadership in fullerene and Repista-based product development, Dr. Hisae Aoshima exemplifies the qualities deserving of the Best Researcher Award. Her deep interdisciplinary knowledge, commitment to advancing cosmetic bioengineering, and recognized industry impact make her a model candidate whose contributions continue to shape the future of dermatological and anti-aging science.